Global Acid Lipase Deficiency Market, By Types (Wolman Disease, Cholesteryl Ester Storage Disease (CESD) and Others), By Treatment Type (Medication, Hematopoietic Stem Cell Transplantation, Enzyme Replacement Therapy and Others), By Route of Administration (Oral, Parenteral), By End Users (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Acid Lipase Deficiency Market
Acid lipase deficiency market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 11.30% in the above mentioned forecast period and would likely to reach an estimated value of 1.34 billion by 2029.
Lysosomal acid lipase (LAL) deficiency is a rare inherited condition in which the body does not produce enough lysosomal acid lipase (LAL) enzyme, an important enzyme for the breakdown of fatty materials such as cholesteryl esters and triglycerides. As a result, a large amount of fatty material accumulates in body organs such as the spleen, liver, and gut. Wolman disease (WD) and Cholesteryl Ester Storage Disease are two autosomal recessive disorders caused by LAL deficiency (CESD). LAL deficiency is caused by a genetic mutation in the LIPA gene, resulting in a decrease or loss of the Lysosomal Acid Lipase (LAL) enzyme.
The increasing use of enzyme replacement therapy for treatment is expected to boost market growth. A large patient pool and a high prevalence of lysosomal acid lipase deficiency are expected to have a significant impact on the demand for novel treatment. Another important factor influencing the growth of this market is the government's substantial financial support and the competitive landscape of pharmaceutical companies, both of which will create new opportunities that will impact the market's growth during the forecast period. The FDA's approval of Sebelipase (Kanuma), the first drug to treat LAL-D, boosted market growth. The drug was created using Enzyme Replacement Therapy (ERT), which aided in the growth of the ERT market. The increasing number of liver transplants is driving up the LAL-D market.
However, disease diagnosis remains poor because the vast majority of people are unaware of their condition and go undiagnosed. There is an urgent need to raise awareness about the importance of early disease detection. Furthermore, inadequacy for therapeutics and high treatment costs are major market restraints.
This acid lipase deficiency market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Acid lipase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Acid Lipase Deficiency Market Scope and Market Size
The acid lipase deficiency market is segmented of the basis of types, treatment, route of administration, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- Based on types, the acid lipase deficiency market is segmented into Wolman disease, Cholesteryl Ester Storage Disease (CESD) and others.
- The treatment segment for acid lipase deficiency market includes medication, hematopoietic stem cell transplantation, enzyme replacement therapy and others.
- On the basis of route of administration, acid lipase deficiency market is segmented into oral and parenteral.
- Based on end-user, the acid lipase deficiency market is segmented into hospitals, homecare, specialty clinics and others
- Acid lipase deficiency market has also been segmented based on the distribution channel into hospital, pharmacy, online pharmacy, retail pharmacy and others.
Acid Lipase Deficiency Market Country Level Analysis
Acid lipase deficiency market is analyzed and market size information is provided by the country, types, treatment, route of administration, end-user and distribution channel as referenced above.
The countries covered in the acid lipase deficiency market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America is expected to dominate the lysosomal acid lipase (LAL) deficiency treatment market due to its rapid novel innovations, drug development, and research. The Food and Drug Administration (FDA) has approved genetically modified organisms (GMO) chickens to produce recombinant human lysosomal acid lipase (LAL) protein in their eggs for the treatment of lysosomal acid lipase (LAL) deficiency in Americans. Europe is expected to be the second largest region for LAL deficiency treatment. Kanuma has been granted marketing authorization by the European Commission for the treatment of LAL deficiency in patients of all ages, which is expected to fuel the company's growth in the region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Acid lipase deficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Acid Lipase Deficiency Market Share Analysis
Acid lipase deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Acid lipase deficiency market research.
Some of the major players operating in the Acid lipase deficiency market are lexion Pharmaceuticals, Inc, Synageva BioPharma Corp, ArmaGen, Bellicum Pharmaceuticals, Inc, Amicus Therapeutics, Inc. Sun Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, Merz Pharma, Medytox, Smith+Nephew, Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, NorthStar Rx LLC, and Par Pharmaceutical, among others.